Repetitive Transcranial Magnetic Stimulation for the Treatment of Resistant Depression: A Scoping Review
Open accessThe DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Abstract
Treatment-resistant depression (TRD) is associated with significant disability, and due to its high prevalence, it results in a substantive socio-economic burden at a global level. TRD is the inability to accomplish and/or achieve remission after an adequate trial of antidepressant treatments. Studies comparing repetitive transcranial magnetic stimulation (rTMS) with electroconvulsive therapy (ECT) and pharmacotherapy have revealed evidence of the therapeutic efficacy of rTMS in TRD. These findings suggest a crucial role for rTMS in the management of TRD. This article aims to conduct a comprehensive scoping review of the current literature concerning the use of rTMS and its therapeutic efficacy as a treatment modality for TRD. PubMed, PsycINFO, Medline, Embase, and Cinahl were used to identify important articles on rTMS for TRD. The search strategy was limited to English articles within the last five years of data publication. Articles were included if they reported on a completed randomized controlled trial (RCT) of rTMS intervention for TRD. The exclusion criteria involved studies with rTMS for the treatment of conditions other than TRD, and study and experimental protocols of rTMS on TRD. In total, 17 studies were eligible for inclusion in this review. The search strategy spanned studies published in the last five years, to the date of the data search (14 February 2022). The regional breakdown of the extracted studies was North American (n = 9), European (n = 5), Asian (n = 2) and Australian (n = 1). The applied frequencies of rTMS ranged from 5 Hz to 50 Hz, with stimulation intensities ranging from 80% MT to 120% MT. Overall, 16 out of the 17 studies suggested that rTMS treatment was effective, safe and tolerated in TRD. For patients with TRD, rTMS appears to provide significant benefits through the reduction of depressive symptoms, and while there is progressive evidence in support of the same, more research is needed in order to define standardized protocols of rTMS application in terms of localization, frequency, intensity, and pulse parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust evidence (e.g., Wallman et al., 2022;Zis et al., 2020) has demonstrated the safety and tolerability of rTMS and has suggested that it is superior to sham stimulation on variables of depression severity, response, and remission in adults across the lifespan (Adu et al., 2022;De Risio et al., 2020;Gaynes et al., 2014).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Adu et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhao, X., Li, Y., Tian, Q., Zhu, B., & Zhao, Z. (2019) · Journal of International Medical Research · doi:10.1177/0300060518817417 · Cited by 160 · cited 15×
“(2019) [56], elderly depressed patients were randomized into two groups of 29, with one group receiving rTMS and the other as a control group, while another group of 30 healthy volunteers were given rTMS.”
BackgroundMethodInfluentialRetractedRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“The World Health Organization has recently reported that depression ranks among the leading causes of disability worldwide [64].”
BackgroundNON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
A scoping review of scoping reviews: advancing the approach and enhancing the consistency
Pham, M. T., Rajić, A., Greig, J. D., Sargeant, J. M., Papadopoulos, A., & McEwen, S. A. (2014) · Research Synthesis Methods · doi:10.1002/jrsm.1123 · Cited by 3,078
Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation
Chen, R., Classen, J., Gerloff, C., Celnik, P., Wassermann, E. M., Hallett, M., & Cohen, L. G. (1997) · Neurology · doi:10.1212/wnl.48.5.1398 · Cited by 2,128 · cited 1×
“While high-frequency rTMS is deemed to produce a stimulating effect on the cerebral cortex, low-frequency rTMS is believed to have an inhibitory effect [26].”
BackgroundO’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910 · cited 3×
“The stimulation of the DLPFC is significantly associated with the enhancement of the neurocognitive domains, and rTMS appears to reduce depressive symptoms, with a subsequent improvement in the neurocognitive functions of TRD patients [30,70,71].”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
Risk factors for suicide in individuals with depression: a systematic review
Hawton, K., Casañas i Comabella, C., Haw, C., & Saunders, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.004 · Cited by 1,469 · cited 1×
“Effective treatment of MDD is available in the form of psychopharmacology, psychotherapy, electroconvulsive therapy (ECT), and other non-invasive brain stimulation methods [5], but affected patients frequently experience relapses and persistent life dysfunction [6], with associated suicidal ideation [7].”
BackgroundDiagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380 · cited 2×
“Because about 50 to 60% of MDD patients fail to attain a reasonable therapeutic response despite being treated with antidepressants, TRD is relatively common in clinical practice [9].”
BackgroundBlumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363 · cited 6×
“Sequential bilateral treatment may be an optimal form of rTMS when used for TRD in older adults nil DM Blumberger et al. (2018) [35] Canada Randomized noninferiority trial 18–65 years 414 L-DLPFC Change in the score of depression symptoms as read on HRSD-17 HRSD-17 QIDS-SR BSI-A DS-30 Five days a…”
BackgroundMethodInfluentialPascual-Leone, A., Rubio, B., Pallardó, F., & Catalá, M. D. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01219-6 · Cited by 1,229 · cited 1×
“The dysfunctions of this brain region are believed to be involved in the pathogenesis of symptoms of depression and cognitive impairment [68,69].”
BackgroundGeorge, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092 · cited 2×
“Though the antidepressant mechanism of multi-coil stimulation and whether it differs from that of standard single-coil stimulation are still being investigated, studies have reported that the depth and direction of the electromagnetic field capable of penetrating the scalp and tissues of the brain for the activation o…”
BackgroundDaily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression
George, M. S., Wassermann, E. M., Williams, W. A., Callahan, A., Ketter, T. A., Basser, P., Hallett, M., & Post, R. M. (1995) · NeuroReport · doi:10.1097/00001756-199510020-00008 · Cited by 954 · cited 1×
“For instance, instead of the usual 10 to 20 trains of 10 Hz stimulation used for a high-frequency left-sided rTMS application [28,29], current trials apply up to about 75 trains for every treatment application daily [30,31].”
BackgroundBasic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS)
Klomjai, W., Katz, R., & Lackmy-Vallée, A. (2015) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2015.05.005 · Cited by 864 · cited 1×
“rTMS has since been studied and evaluated by researchers for its potential therapeutic effect on many neurological and mental health conditions worldwide [24].”
BackgroundDEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797 · cited 1×
“From the earliest conceptualization of TRD in 1974 [12–14], numerous studies have been conducted to determine the most effective treatment strategy for TRD [15,16].”
BackgroundGrimm, S., Beck, J., Schuepbach, D., Hell, D., Boesiger, P., Bermpohl, F., Niehaus, L., Boeker, H., & Northoff, G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.033 · Cited by 686 · cited 1×
“Studies suggest an imbalance in the efficient functioning of the frontal lobe in individuals diagnosed with depression [32].”
BackgroundGeorge, M. S., Wassermann, E. M., Kimbrell, T. A., Little, J. T., Williams, W. E., Danielson, A. L., Greenberg, B. D., Hallett, M., & Post, R. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.12.1752 · Cited by 573 · cited 1×
“For instance, instead of the usual 10 to 20 trains of 10 Hz stimulation used for a high-frequency left-sided rTMS application [28,29], current trials apply up to about 75 trains for every treatment application daily [30,31].”
BackgroundArnsten, A. F. T., & Rubia, K. (2012) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2012.01.008 · Cited by 568 · cited 1×
“The left DLPFC represents an essential brain region for neurocognitive performance connecting to the frontosubcortical brain regions [67].”
BackgroundKlein, E., Kreinin, I., Chistyakov, A., Koren, D., Mecz, L., Marmur, S., Ben-Shachar, D., & Feinsod, M. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.4.315 · Cited by 542 · cited 1×
“Hence, researchers have treated patients with low-frequency rTMS to the right dorsolateral prefrontal cortex (DLPFC), or high-frequency stimulation to the left DLPFC [33,34].”
BackgroundA controlled trial of daily left prefrontal cortex TMS for treating depression
George, M. S., Nahas, Z., Molloy, M., Speer, A. M., Oliver, N. C., Li, X.-B., Arana, G. W., Risch, S. C., & Ballenger, J. C. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01048-9 · Cited by 464 · cited 1×
“Hence, researchers have treated patients with low-frequency rTMS to the right dorsolateral prefrontal cortex (DLPFC), or high-frequency stimulation to the left DLPFC [33,34].”
BackgroundMolendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.98 · Cited by 437 · cited 1×
“Inflammatory factors such as interleukin (IL)-1 [58], tumor necrosis factor (TNF)-a [59], nuclear factor-kappaB (NF-jB) [60], and brain-derived neurotrophic factor (BDNF) have been implicated in the causative mechanism of depression [61].”
BackgroundRecent developments and current controversies in depression
Ebmeier, K. P., Donaghey, C., & Steele, J. D. (2006) · The Lancet · doi:10.1016/s0140-6736(06)67964-6 · Cited by 434 · cited 1×
“Depression is a global burden and a debilitating condition that exacts a serious personal, social, and economic toll [62]; it is associated with extreme consequences such as increased mortality, disability, and secondary morbidity [63].”
BackgroundFitzgerald, P. B., Benitez, J., de Castella, A., Daskalakis, Z. J., Brown, T. L., & Kulkarni, J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.88 · Cited by 363 · cited 1×
“The dysfunctions of this brain region are believed to be involved in the pathogenesis of symptoms of depression and cognitive impairment [68,69].”
BackgroundGaynes, B. N., Lloyd, S. W., Lux, L., Gartlehner, G., Hansen, R. A., Brode, S., Jonas, D. E., Evans, T. S., Viswanathan, M., & Lohr, K. N. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08815 · Cited by 347 · cited 2×
“A wide variety of treatment choices, including pharmacological and nonpharmacological interventions and somatic treatments, represent treatment options which are available for the management of TRD [18].”
BackgroundInfluentialThe burden of disease for treatment-resistant depression.
Greden, J. F. (2001) · PubMed · Cited by 279
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237 · cited 1×
“However, the decreasing therapeutic efficacy of antidepressant medications following at least two failed treatments, coupled with their potential side effects [19,20], has led to research into alternative treatment modalities, including repetitive transcranial magnetic stimulation (rTMS) [18].”
BackgroundInfluentialDefining and Measuring Functional Recovery from Depression
Greer, T. L., Kurian, B. T., & Trivedi, M. H. (2010) · CNS Drugs · doi:10.2165/11530230-000000000-00000 · Cited by 222 · cited 1×
“Effective treatment of MDD is available in the form of psychopharmacology, psychotherapy, electroconvulsive therapy (ECT), and other non-invasive brain stimulation methods [5], but affected patients frequently experience relapses and persistent life dysfunction [6], with associated suicidal ideation [7].”
BackgroundChen, J., Zhou, C., Wu, B., Wang, Y., Li, Q., Wei, Y., Yang, D., Mu, J., Zhu, D., Zou, D., et al. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.09.007 · Cited by 213 · cited 2×
“Furthermore, both low and high frequencies of rTMS application targeted to either the left or right DLPFC had the same therapeutic efficacy [36].”
BackgroundThe economic and social burden of depression.
Sartorius, N. (2001) · PubMed · Cited by 188
Yesavage, J. A., Fairchild, J. K., Mi, Z., Biswas, K., Davis-Karim, A., Phibbs, C. S., Forman, S. D., Thase, M., Williams, L. M., Etkin, A., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.1483 · Cited by 164 · cited 3×
“(2018) [49] USA A doubleblind, shamcontrolled randomized clinical 18–80 years 164 L-PFC Remission of depression symptoms And the severity of depression symptoms HRSD BDI 3 weeks MagPro R30 device with Cool-B65-A/P coil.”
BackgroundMethodMaes, M., Song, C., & Yirmiya, R. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2012.718331 · Cited by 159 · cited 1×
“Inflammatory factors such as interleukin (IL)-1 [58], tumor necrosis factor (TNF)-a [59], nuclear factor-kappaB (NF-jB) [60], and brain-derived neurotrophic factor (BDNF) have been implicated in the causative mechanism of depression [61].”
BackgroundDoktorchik, C., Patten, S., Eastwood, C., Peng, M., Chen, G., Beck, C. A., Jetté, N., Williamson, T., & Quan, H. (2019) · BMC Psychiatry · doi:10.1186/s12888-018-1990-6 · Cited by 156 · cited 1×
“Major depressive disorder (MDD) is a mood disorder characterized by a depressed mood and/or a lack of interest or pleasure in previously rewarding or enjoyable activities, fatigue, disturbed sleep, the loss of appetite, and somatic and psychological symptoms [1,2].”
BackgroundCroarkin, P. E., Elmaadawi, A. Z., Aaronson, S. T., Schrodt, G. R., Holbert, R. C., Verdoliva, S., Heart, K. L., Demitrack, M. A., & Strawn, J. R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-00829-y · Cited by 144 · cited 5×
“The brain site for rTMS application employed by the studies ranged from the left PFC (n = 5) [42,46,49,50,53] to the left DLPFC (n = 4) [35,48,52,56].”
BackgroundMethodInfluentialKarson, A., Demirtaş, T., Bayramgürler, D., Balcı, F., & Utkan, T. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12037 · Cited by 143 · cited 1×
“Inflammatory factors such as interleukin (IL)-1 [58], tumor necrosis factor (TNF)-a [59], nuclear factor-kappaB (NF-jB) [60], and brain-derived neurotrophic factor (BDNF) have been implicated in the causative mechanism of depression [61].”
BackgroundValero-Cabré, A., Payne, B. R., & Pascual-Leone, A. (2007) · Experimental Brain Research · doi:10.1007/s00221-006-0639-8 · Cited by 137 · cited 1×
“Studies have it that the effectiveness of rTMS treatment regarding the modulation of neural activities greatly depends on the frequency applied and other stimulation parameters [72].”
BackgroundDefining Treatment-Resistant Depression: A Comprehensive Review of the Literature
Trevino, K., McClintock, S. M., Fischer, N. M., Vora, A., & Husain, M. M. (2014) · Annals of Clinical Psychiatry · doi:10.1177/104012371402600310 · Cited by 130 · cited 1×
“When a patient with MDD cannot attain remission or an adequate therapeutic response while being treated with one or more antidepressants, the patient is said to have developed treatment-resistant depression (TRD), and is diagnosed as such [8].”
BackgroundSomani, A., & Kar, S. K. (2019) · General Psychiatry · doi:10.1136/gpsych-2019-100074 · Cited by 126
The Cost Consequences of Treatment-Resistant Depression
Russell, J. M., Hawkins, K., Ozminkowski, R. J., Orsini, L., Crown, W. H., Kennedy, S., Finkelstein, S., Berndt, E., & Rush, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0309 · Cited by 117 · cited 1×
“As a result of the potential, high, direct and indirect medical costs, which further increase the severity of TRD, clinicians are in search of empirical evidence to guide in the choice of the most effective treatment for TRD [17].”
BackgroundGuo, Q., Li, C., & Wang, J. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0185-3 · Cited by 95 · cited 12×
“This study supports the clinical observation that a combination of interventions, including rTMS, effectively achieves symptom remission in 39.0% of veterans with MDD who were previously treatmentresistant.”
BackgroundMethodInfluentialWall, C. A., Croarkin, P. E., Sim, L. A., Husain, M. M., Janicak, P. G., Kozel, F. A., Emslie, G. J., Dowd, S. M., & Sampson, S. M. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07003 · Cited by 92
Hovington, C. L., McGirr, A., Lepage, M., & Berlim, M. T. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.783993 · Cited by 85 · cited 1×
“Major depressive disorder (MDD) is a mood disorder characterized by a depressed mood and/or a lack of interest or pleasure in previously rewarding or enjoyable activities, fatigue, disturbed sleep, the loss of appetite, and somatic and psychological symptoms [1,2].”
BackgroundPhilip, N. S., Dunner, D. L., Dowd, S. M., Aaronson, S. T., Brock, D. G., Carpenter, L. L., Demitrack, M. A., Hovav, S., Janicak, P. G., & George, M. S. (2016) · Brain Stimulation · doi:10.1016/j.brs.2015.11.007 · Cited by 79 · cited 2×
“This result contrasts a trial in which patients were randomized to once-a-month rTMS maintenance treatment and an observation-only group, the results of which failed to predict any statistically significant difference between the two groups at the end of a 1-year study period [57].”
ResultQin, T., Fang, F., Song, M., Li, R., Ma, Z., & Ma, S. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.09.039 · Cited by 79 · cited 1×
“Inflammatory factors such as interleukin (IL)-1 [58], tumor necrosis factor (TNF)-a [59], nuclear factor-kappaB (NF-jB) [60], and brain-derived neurotrophic factor (BDNF) have been implicated in the causative mechanism of depression [61].”
BackgroundSerafini, G., Pompili, M., Innamorati, M., Dwivedi, Y., Brahmachari, G., & Girardi, P. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990293 · Cited by 78 · cited 1×
“Effective treatment of MDD is available in the form of psychopharmacology, psychotherapy, electroconvulsive therapy (ECT), and other non-invasive brain stimulation methods [5], but affected patients frequently experience relapses and persistent life dysfunction [6], with associated suicidal ideation [7].”
BackgroundIwabuchi, S. J., Auer, D. P., Lankappa, S. T., & Palaniyappan, L. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2019.02.012 · Cited by 73 · cited 3×
“(2019) [45] Canada RCT 18–70 years 27 DLPFC rTMS Treatment response in TRD HAM-D BDI 4 weeks Magstim Super Rapid 2 Plus 1 stimulator 70 mm Double Air Film Coil.”
BackgroundMethodA randomized, sham-controlled study of maintenance rTMS for treatment-resistant depression (TRD)
Benadhira, R., Thomas, F., Bouaziz, N., Braha, S., Andrianisaina, P. S., Isaac, C., Moulier, V., & Januel, D. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.029 · Cited by 72 · cited 5×
“The brain site for rTMS application employed by the studies ranged from the left PFC (n = 5) [42,46,49,50,53] to the left DLPFC (n = 4) [35,48,52,56].”
BackgroundMethodInfluentialTrevizol, A. P., Goldberger, K. W., Mulsant, B. H., Rajji, T. K., Downar, J., Daskalakis, Z. J., & Blumberger, D. M. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5091 · Cited by 70 · cited 12×
“Author (Year) Country of Origin Study Design Age Range Number of Participants Targeted Brain Region Targeted Symptom Measurement Duration of Treatment Coil/ rTMS Parameters/ Stimulation Method Outcome/ Significant Improvements/ Effect Size Assessment and FollowUp Conclusions Side Effects Zhao et al. (2019) [56] China…”
BackgroundMethodInfluentialLangguth, B., Wiegand, R., Kharraz, A., Landgrebe, M., Marienhagen, J., Frick, U., Hajak, G., & Eichhammer, P. (2007) · PubMed · Cited by 68
Fitzgerald, P. B., Hoy, K. E., Reynolds, J., Singh, A., Gunewardene, R., Slack, C., Ibrahim, S., & Daskalakis, Z. J. (2020) · Brain Stimulation · doi:10.1016/j.brs.2019.09.001 · Cited by 68 · cited 8×
“Suicidal ideation, worsening depression during week 4, suicide attempt during week 6 Fitzgerald et al. (2020) [27] Australia Four armRCT Adults 300 L-DLPFC & R DLPFC Response and remission rates of depression symptoms HRSD-17 4 weeks Medtronic Magpro30 magnetic stimulators with fluid-filled 70 mm…”
BackgroundMethodInfluentialMcPherson, S., Cairns, P., Carlyle, J., Shapiro, D. A., Richardson, P., & Taylor, D. (2005) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2004.00498.x · Cited by 66 · cited 1×
“The most effective treatment of TRD remains uncertain due to the limited validated pharmacological and psychotherapeutic approaches [37,38].”
BackgroundWall, C. A., Croarkin, P. E., Maroney-Smith, M. J., Haugen, L. M., Baruth, J. M., Frye, M. A., Sampson, S. M., & Port, J. D. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2015.0217 · Cited by 62
Hernández-Ribas, R., Deus, J., Pujol, J., Segalàs, C., Vallejo, J., Menchón, J. M., Cardoner, N., & Soriano-Mas, C. (2013) · Brain Stimulation · doi:10.1016/j.brs.2012.01.001 · Cited by 59 · cited 1×
“However, the pathophysiology of depression is assumed to involve a variety of deeper frontal brain regions [65,66].”
BackgroundKozel, F. A., George, M. S., & Simpson, K. N. (2004) · PubMed · Cited by 58
Depression in adults: drug and physical treatments.
Barbui, C., Butler, R., Cipriani, A., Geddes, J. R., & Hatcher, S. (2007) · Europe PMC (PubMed Central) · Cited by 56
Targeting location relates to treatment response in active but not sham rTMS stimulation
Rosen, A. C., Bhat, J. V., Cardenas, V. A., Ehrlich, T. J., Horwege, A. M., Mathalon, D. H., Roach, B. J., Glover, G. H., Badran, B. W., Forman, S. D., et al. (2021) · Brain Stimulation · doi:10.1016/j.brs.2021.04.010 · Cited by 55 · cited 13×
“Author (Year) Country of Origin Study Design Age Range Number of Participants Targeted Brain Region Targeted Symptom Measurement Duration of Treatment Coil/ rTMS Parameters/ Stimulation Method Outcome/ Significant Improvements/ Effect Size Assessment and FollowUp Conclusions Side Effects Zhao et al. (2019) [56] China…”
BackgroundInfluentialA Critical Overview of the Pharmacologic Management of Treatment-Resistant Depression
Nierenberg, A. A., Katz, J., & Fava, M. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.01.001 · Cited by 52 · cited 1×
“The most effective treatment of TRD remains uncertain due to the limited validated pharmacological and psychotherapeutic approaches [37,38].”
BackgroundEitan, R., & Lerer, B. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.2/reitan · Cited by 50
Theleritis, C., Sakkas, P., Paparrigopoulos, T., Vitoratou, S., Tzavara, C., Bonaccorso, S., Politis, A., Soldatos, C. R., & Psarros, C. (2017) · The Journal of ECT · doi:10.1097/yct.0000000000000387 · Cited by 48 · cited 3×
“The brain site for rTMS application employed by the studies ranged from the left PFC (n = 5) [42,46,49,50,53] to the left DLPFC (n = 4) [35,48,52,56].”
BackgroundMethodKedzior, K. K., Rajput, V., Price, G., Lee, J., & Martin-Iverson, M. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-163 · Cited by 40 · cited 1×
“The stimulation of the DLPFC is significantly associated with the enhancement of the neurocognitive domains, and rTMS appears to reduce depressive symptoms, with a subsequent improvement in the neurocognitive functions of TRD patients [30,70,71].”
BackgroundTherapy-Resistant Depressions: Symptoms and Syndromes: Contibutions to Symptomatology and Syndromes
Heimann, H. (1974) · Pharmacopsychiatry · doi:10.1055/s-0028-1094412 · Cited by 38
Zhao, Y. J., Tor, P. C., Khoo, A. L., Teng, M., Lim, B. P., & Mok, Y. M. (2018) · Neuromodulation: Technology at the Neural Interface · doi:10.1111/ner.12723 · Cited by 36 · cited 9×
“Studies comparing repetitive transcranial magnetic stimulation (rTMS) with electroconvulsive therapy (ECT) and pharmacotherapy have revealed evidence of the therapeutic efficacy of rTMS in TRD, and these findings suggest a key role of rTMS in the management of TRD [22].”
BackgroundInfluentialTarhan, N., Sayar, G. H., Tan, O., & Kağan, G. (2012) · Clinical EEG and Neuroscience · doi:10.1177/1550059412449752 · Cited by 35 · cited 1×
“High-frequency rTMS over the DLPFC has been used in the most recent trials—a choice guided by the positive outcome results for this approach [73].”
MethodTranscranial magnetic stimulation in depression – Lessons from the multicentre trials
Schönfeldt-Lecuona, C., Cárdenas-Morales, L., Freudenmann, R. W., Kammer, T., & Herwig, U. (2010) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-2010-0561 · Cited by 34 · cited 1×
“The stimulation of the DLPFC is significantly associated with the enhancement of the neurocognitive domains, and rTMS appears to reduce depressive symptoms, with a subsequent improvement in the neurocognitive functions of TRD patients [30,70,71].”
BackgroundrTMS with a two-coil array: Safety and efficacy for treatment resistant major depressive disorder
Carpenter, L. L., Aaronson, S. T., Clarke, G. N., Holtzheimer, P. E., Johnson, C. W., McDonald, W. M., Stannard, E. L., & Schneider, M. B. (2017) · Brain Stimulation · doi:10.1016/j.brs.2017.06.003 · Cited by 34 · cited 3×
“For instance, Carpenter et al. (2017) and Kavanaugh et al. (2018) targeted the effectiveness and safety of a two-coil rTMS device in their study subjects.”
BackgroundMethodResultvan Eijndhoven, P., Bartholomeus, J., Möbius, M., de Bruijn, A., Ferrari, G. R. A., Mulders, P. C. R., Schene, A. H., Schutter, D. J. L. G., Spijker, J., & Tendolkar, I. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.055 · Cited by 33 · cited 4×
“The brain site for rTMS application employed by the studies ranged from the left PFC (n = 5) [42,46,49,50,53] to the left DLPFC (n = 4) [35,48,52,56].”
MethodResultInfluentialPradhan, B., Parikh, T., Makani, R. D., & Sahoo, M. (2015) · Depression Research and Treatment · doi:10.1155/2015/842817 · Cited by 32 · cited 1×
“MDD is a significant public health concern that affects approximately 300 million people globally, is a major leading cause of morbidity, and contributes immensely to the global burden of disease [3,4].”
BackgroundKavanaugh, B. C., Aaronson, S. T., Clarke, G. N., Holtzheimer, P. E., Johnson, C. W., McDonald, W. M., Schneider, M. B., & Carpenter, L. L. (2018) · The Journal of ECT · doi:10.1097/yct.0000000000000494 · Cited by 25 · cited 15×
“Author (Year) Country of Origin Study Design Age Range Number of Participants Targeted Brain Region Targeted Symptom Measurement Duration of Treatment Coil/ rTMS Parameters/ Stimulation Method Outcome/ Significant Improvements/ Effect Size Assessment and FollowUp Conclusions Side Effects Zhao et al. (2019) [56] China…”
BackgroundInfluentialKito, S., Miyazi, M., Nakatani, H., Matsuda, Y., Yamazaki, R., Okamoto, T., & Igarashi, Y. (2019) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12066 · Cited by 22 · cited 3×
“…5, 10, 15, 20 sessions and one-week posttreatment “Standard” 4-week rTMS treatment is not effective in chronic, severe TRD Mild to moderate headache Kito et al. (2019) [50] Japan Randomized open-label trial 25–75 years 30 (28 com-pleted) L-PFC Remissions in depression symptoms QIDS PHQ-9…”
BackgroundMethodFilipčić, I., Filipčić, I. Š., Sučić, S., Milovac, Ž., Gereš, N., Matić, K., Ružić, M. Ć., Penić, S. Z., Orgulan, I., Požgaj, V., et al. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01141-y · Cited by 19 · cited 3×
“(2018) [47] also reported cases of suicidal ideation in three active and four sham participants, though no suicides or seizures occurred during the study.”
BackgroundMethodPain during transcranial magnetic stimulation in youth.
Coarkin, P. E., Wall, C. A., King, J. D., Kozel, F. A., & Daskalakis, Z. J. (2011) · Europe PMC (PubMed Central) · Cited by 18
Segev, A., Spellun, J., & Bloch, Y. (2014) · Journal of Ect · doi:10.1097/yct.0000000000000183 · Cited by 12
Barbini, B., Attanasio, F., Manfredi, E., Cavallini, M., Zanardi, R., & Colombo, C. (2021) · International journal of psychiatry in clinical practice · doi:10.1080/13651501.2021.1894579 · Cited by 12 · cited 12×
“Author (Year) Country of Origin Study Design Age Range Number of Participants Targeted Brain Region Targeted Symptom Measurement Duration of Treatment Coil/ rTMS Parameters/ Stimulation Method Outcome/ Significant Improvements/ Effect Size Assessment and FollowUp Conclusions Side Effects Zhao et al. (2019) [56] China…”
BackgroundMethodInfluentialRoach, A. E., Hines, C. E., Stafford, J., & Mooney, S. (2020) · Journal of Ect · doi:10.1097/yct.0000000000000680 · Cited by 7 · cited 9×
“Author (Year) Country of Origin Study Design Age Range Number of Participants Targeted Brain Region Targeted Symptom Measurement Duration of Treatment Coil/ rTMS Parameters/ Stimulation Method Outcome/ Significant Improvements/ Effect Size Assessment and FollowUp Conclusions Side Effects Zhao et al. (2019) [56] China…”
InfluentialTranscranial Magnetic Stimulation: Potential New Treatment for Resistant Depression
Schatzberg, A. F., Demitrack, M. A., O†Reardon, J. P., Richelson, E., & Thase, M. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0219 · Cited by 5
Treatment-refractory depression: Definitions and characteristics
Berman, R. M., Narasimhan, M., & Charney, D. S. (1997) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1997)5:4<154::aid-da2>3.0.co;2-d
Research works printed but not linked: 2
- Fawcett, 1985, Treatment refractory depression, Common Treat. Probl. Depress., 5, 1
- Nierenberg, 1991, Methodological considerations for the study of treatment-resistant depression, Adv. Neuropsychiatry Psychopharmacol., 2, 83
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Effects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 209
“A recent review evaluating the effectiveness of repetitive TMS (rTMS) to the PFC for TRD concludes that rTMS is reliable, well-tolerated, and efficacious (Adu et al., 2022).”
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Samojedny, S., Czechowska, E., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911423 · Cited by 23
Yılmaz, N. S., Şen, B., Karadag, R. F., Aslan, S., Ertek, İ. E., Bozkurt, A., Çiçek, S., Bolu, A., Ucar, H., Koçak, C., et al. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02553-x · Cited by 21
“rTMS is also an important treatment option in this patient group, and its frequency of use is increasing (Fitzgerald 2020; Adu et al. 2022; Baeken and De Raedt 2022; Williams et al. 2021).”
BackgroundWang, Y., Dong, T., Li, X. J., Zhao, H., Yang, L., Xu, R., Fu, Y., Li, L., Gai, X., & Qin, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1219590 · Cited by 47
Metadata
- Authors
- Adu, M. K., Shalaby, R., Chue, P., & Agyapong, V. I. O.
- Affiliations
- University of Alberta (CA)
- Dalhousie University (CA)
- Corresponding author
- Adu, Medard Kofi
- Venue
- Behavioral Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-17
- Volume
- 12
- Issue
- 6
- Pages
- 195
- ISSN
- 2076-328X (ISSN-L)
- PMC
- PMC9220129
- OpenAlex
- W4283019182
- Cited by
- 31
- References
- 79
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 2
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Behavioral Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mental Health Foundation
- Douglas Harden Trust Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- repetitive transcranial magnetic stimulation, treatment-resistant depression, electroconvulsive therapy, antidepressant treatment, randomized controlled trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
